4D Molecular Therapeutics
FDMT
120 hedge funds and large institutions have $151M invested in 4D Molecular Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 22 closing their positions.
16% more call options, than puts
Call options by funds: $171K | Put options by funds: $147K
7% more capital invested
Capital invested by funds: $141M → $151M (+$10.1M)
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
4% less funds holding
Funds holding: 125 → 120 (-5)
5.85% less ownership
Funds ownership: 93.06% → 87.21% (-5.9%)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.47M |
| 2 |
Two Sigma Advisers
New York
|
+$889K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$699K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$606K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$3.11M |
| 2 |
Morgan Stanley
New York
|
-$3M |
| 3 |
VA
VR Adviser
New York
|
-$2.19M |
| 4 |
BlackRock
New York
|
-$1.89M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.33M |
FDMT Hedge Fund Activity: Q2 2025 in Review
120 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2025, worth a combined $151M — up 7.2% from $141M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of FDMT and 17 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 43 added.
The largest buyer was Federated Hermes, adding an estimated $1.47M. The largest seller was Redmile Group, cutting an estimated $3.11M.
- 120 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2025, down from 125 in Q1 2025.
- Funds reported $151M of 4D Molecular Therapeutics stock for Q2 2025, up 7.2% quarter-over-quarter.
- 17 funds opened new 4D Molecular Therapeutics positions in Q2 2025 and 22 closed out, a net change of -5 holders.
- The largest 4D Molecular Therapeutics buyer in Q2 2025 was Federated Hermes, an estimated $1.47M added.
- The largest 4D Molecular Therapeutics seller in Q2 2025 was Redmile Group, an estimated $3.11M sold.
Based on aggregated 13F filings for Q2 2025.